



10th International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain
Preliminary Programme

Friday, 5 September 2025
Main Track

09:00 – 09:35	Welcome & Introduction Chairs: Anna Sureda (ES) & Alex Rampotas (UK) The EBMT: 2025 and beyond The Next-Gen: The EBMT Trainee Committee The EBMT Exam: Future Plans	Anna Sureda (ES) Alex Rampotas (UK) Isabel Sanchez - Ortega (ES)
09:35 – 10:45	Session I: Transplantation and Cellular Therapy: Fundamentals and Framework Chairs: Candice Hendricks (RSA) & John Snowden (UK) Hematopoietic cell transplantation: Why and How It Works? HLA System and donor selection CAR-T: The Game Changers <i>Case presentation:</i> Post-transplant Cyclophosphamide as GvHD prophylaxis in Matched Sibling Donor in patients with β -Thalassemia Major – A Single Centre Experience	John Snowden (UK) Neema Mayor (UK) Alberto Mussetti (ES) <i>To be announced</i>
10:30 – 10:40	<i>Case presentation:</i> Post-CART viral reactivations in paediatric patients: experience in a tertiary care centre	<i>To be announced</i>
10:40 – 10:45	Discussion and Q&A	
10:45 – 11:15	Coffee Break	
11:15 – 12:30	Session II: Transplant Science Chairs: Annalisa Ruggeri (IT) & Luca Vinci (DE) HSC Mobilization, Collection, Processing and Preservation Conditioning regimen and intensity Engraftment and Graft Dynamics <i>Case presentation:</i> Severe and fatal central nervous system toxicity after fludarabine, thiotepea and melphalan conditioning for allogeneic stem cell transplantation	Sara Vallejo Diez (ES) Florent Malard (FR) Annalisa Ruggeri (IT) Pleun Schonewille (NL)
12:10 – 12:30	Discussion and Q&A	
12:30 – 13:15	Lunch Break	
13:15 – 14:00	Industry Symposium by Therakos: “Uncovering emerging evidence to treat GvHD with ECP - Mastering the art of GvHD therapy”	
13:15 – 13:20	Introduction	
13:20 – 13:35	Prof Anna Sureda , Catalan Institute of Oncology, Duran I Reynals Hospital, Spain How to treat GvHD with ECP – current real-world management of GvHD in Spain Dr Guillermo Ortí , University Hospital Vall d’Hebron, Spain	
13:35 – 13:50	Evidence for treatment of chronic GvHD using ECP – a future backbone for GvHD therapy Dr Laura Fox , University Hospital Vall d’Hebron, Spain	
13:50 – 14:00	Discussion	

14:00 – 15:30

Session III: GVHD

Chairs: Mette Hazenberg (NL) & Fabio Ciceri (IT)

14:00 – 14:15

GVHD Biology: What We Know So Far

Mette Hazenberg (NL)

14:15 – 14:30

Acute GVHD: Diagnosis, Prevention, and Treatment

Zinaida Peric (HR)

14:30 – 14:45

The Forgotten Site: Stomach GVHD in Allogeneic Stem Cell Transplantation

Jana Gawron (DE)

14:45 – 14:55

Case presentation:

Effective treatment with Mesenchymal Stromal Cells for refractory Graft-Versus-Host

Disease after allo-HCT complicated by BK virus-associated haemorrhagic cystitis in a patient with AML

Maddalena V. Ponti (IT)

14:55 – 15:05

Case presentation:

Hyperbilirubinemia in the 5th Month Post-Allogeneic Transplantation

Marina Herrero (ES)

15:05 – 15:30

Discussion and Q&A

15:30 – 16:00

Coffee Break

16:00 – 17:15

Session IV: Late Complications, Ethics and Patient Perspectives

Chairs: Carmelo Gurnari (IT) & Giorgio Orofino (IT)

16:00 – 16:15

Late Complications after transplantation

Michelle Kenyon (UK)

16:15 – 16:30

Effective Communication for Transplant and CT Physicians

Carmelo Gurnari (IT)

16:30 – 16:40

CAR-T survivorship

Anna Barata (US)

16:40 – 16:50

Patient and caregiver outcomes after CAR-T therapy

David Aguilar Prieto (ES)

16:50 – 17:00

Case presentation:

Late cytopenia post-CAR T-cell infusion and clonal haematopoiesis: a case report Desirée Eboli (IT)

17:00 – 17:15

Discussion and Q&A

17:15 – 18:00

Keynote Lecture

Chair: Alex Rampotas (UK)

Endothelia and early complications after HCT

Enric Carreras (ES)

18:00 – 18:45

Poster Session

Further information will be available soon.

09:00 – 11:00 Session V: Indications for allogeneic HCT in Adults

Chairs: Donal McLornan (UK) & Moniek de Witte (NL)

- 09:00 – 09:30** Introductory Case-based: Indications of HCT in AML
Indications of HCT in AML
- 09:30 – 10:00** Introductory Case-based: Indications of HCT in MDS
Indications of HCT in MDS
- 10:00 – 10:30** Introductory Case-based: Indications of HCT in MPN
Indications of HCT in MPN
- 10:30 – 11:00** Introductory Case-based: Indications of HCT in Bone marrow failures
Indications of HCT in Bone marrow failures

Fanny Palumbo (IT)
Fabio Ciceri (IT)
Piotr Kacprzyk (PL)
Joanna Drozd-Sokołowska (PL)
Yousif Hameed (UK)
Donal McLornan (UK)
Jamie Macleod (UK)
José Cilleruelo (UK)

11:00 – 11:30 Coffee Break

11:30 – 13:00 Session VI: Transforming Care: HCT and CAR-T Therapies

Chairs: Raffaella Greco (IT) & Nico Gagelmann (DE)

- 11:30 – 11:45** Indications of HCT in ALL
- 11:45 – 12:00** CAR-T for ALL
- 12:00 – 12:15** CAR-T for Myelofibrosis
- 12:15 – 12:30** The alternative HCT: Autoimmune diseases
- 12:30 – 12:45** Emerging CAR-T Indications in Autoimmune diseases
- 12:45 – 13:00** Discussion and Q&A

Sebastian Giebel (PL)
Mike Northend (UK)
Alex Rampotas (UK)
Tobias Alexander (DE)
Raffaella Greco (IT)

13:00 – 14:00 Lunch Break

14:00 – 15:15 Session VII: Lymphoma: Bridging Transplant and CAR-T Therapies

Chairs: Anna Sureda (ES) & Alex Rampotas (UK)

- 14:00 – 14:15** Indications of HCT in Lymphoma
- 14:15 – 14:30** CAR-T for Lymphoma
- 14:30 – 14:45** CAR-T Complications
- 14:45 – 14:55** Case Presentation:
Cyclosporine-Associated Central Pontine Myelinolysis Presenting as Peduncular Hallucinoses Following Allogeneic Hematopoietic Stem Cell Transplantation
- 14:55 – 15:05** Case Presentation:
Hepatic Graft-versus-Host Disease Following Brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma after Allogeneic Transplantation
- 15:05 – 15:15** Discussion and Q&A

Ali Bazarbachi (LB)
Anna Sureda (ES)
Nico Gagelmann (DE)

Camila Donadel (BR)

Elena Bechtold (ES)

15:15 – 15:45 Coffee Break



10th International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain
Preliminary Programme

Saturday, 6 September 2025
Main Track

15:45 – 17:00

Session VIII: Advances and Challenges in Multiple Myeloma

Chairs: Adrian Mosquera Orgueira (ES) & Luis Gerardo Rodríguez-Lobato (ES)

15:45 – 16:00

Indications of HCT in Multiple Myeloma

Patrick Hayden (IE)

16:00 – 16:15

CAR-T for Multiple Myeloma

Luis Gerardo Rodríguez-Lobato (ES)

16:15 – 16:30

Strategies to Overcome Challenges in CAR-T Cell Therapy

Carlos Fernández De Larrea (ES)

16:30 – 16:40

Case presentation:

Daratumumab as a Novel Therapeutic Option for Refractory Pure Red Cell Aplasia

Following Major ABO-Incompatible Allogeneic HSCT

Nevena Besevic (RS)

16:40 – 17:00

Discussion and Q&A

17:00 – 17:45

Keynote Lecture

Chair: Annalisa Ruggeri (IT)

Further information will be available soon.

Éliane Gluckman (FR)

Saturday, 6 September 2025
Nurse Track

09:00 – 11:00	Session I: Preparation, cell collection, conditioning and infusion Chairs: Michelle Kenyon (UK) & Hilda Mekelenkamp (UK)	
09:00 – 09:10	Welcome & Introduction	Hilda Mekelenkamp (NL)
09:10 – 09:30	Right donor, right patient, right time	Annika Kisch (SE)
09:30 – 09:55	Preparing for transplant: all you need to know	Davide Bonomi (IT)
09:55 – 10:15	Conditioning regimens different approaches and why	Marijke Quaghebeur (BE)
10:15 – 10:40	Cell infusion: stem cell, CART and lymphocytes: exploring the differences	Sandrine Bremathas (UK)
10:40 – 11:00	CVCs - evidencing best practice	Solveig Adalsteinsdóttir (SE)
11:00 – 11:30	Coffee Break	
11:30 – 13:00	Session II: Post infusion care Chairs: Claudia Boglione (IT) & Marijke Quaghebeur (BE)	
11:30 – 11:50	Nutritional support – the current guidance	Katie Ahern (IE)
11:50 – 12:15	Infections and keeping our patients safe	Thomas Jézéquel (FR)
12:15 – 12:45	Early complications	Anna Serrahima (ES)
12:45 – 13:00	<i>Case Presentation:</i> Walking on a tightrope to optimize care in an infant undergoing HSCT for severe aplastic anaemia – the nursing story	To be announced
13:00 – 14:00	Lunch Break	
14:00 – 15:15	Session III: Transplant complications Chairs: Thomas Jézéquel (FR) & Anna Serrahima (ES)	
14:00 – 14:15	Acute GvHD & graft management	Silvia Gnecci (IT)
14:15 – 14:30	Chronic GvHD	John Murray (UK)
14:30 – 14:45	GvHD Q&A	
14:45 – 15:00	Conception, sex and sexuality	Iebe de Quick (BE)
15:00 – 15:15	Long term follow-up, QoL, and survivorship	Michelle Kenyon (UK)
15:15 – 15:45	Coffee Break	
15:45 – 16:30	Session IV: Essential update Chairs: Hilda Mekelenkamp (UK) & Annika Kisch (SE)	
15:45 – 16:05	Paediatric update	Hilda Mekelenkamp (UK)
16:05 – 16:25	Evolving treatments in auto-immune disease	Claudia Boglione (IT)
16:25 – 16:30	Closing remarks	Hilda Mekelenkamp (UK)
17:00 – 17:45	Keynote Lecture (Main Room) Chair: Annalisa Ruggeri (IT) <i>Further information will be available soon.</i>	Éliane Gluckman (FR)

Saturday, 6 September 2025
Paediatric Track

09:00 – 11:00	Session I: Leukemias in children (PDWP) Chairs: Krzysztof Kałwak (PL) & Benedetta E. Di Majo (IT)	
09:00 – 09:25	Paediatric ALL TBI vs non-TBI	Krzysztof Kałwak (PL)
09:25 – 09:50	CAR-T cells in B-ALL	Giovanna Lucchini (IT)
09:50 – 10:15	AML in 2025: Who and when to transplant?	Dominik Turkiewicz (SE)
10:15 – 10:40	CML: is there still a role for transplant in the era of TKIs?	Herbert Pichler (AT)
10:40 – 10:50	Case Presentation: Beyond remission: Uncertainties in Late-Onset Hepatic complications after CAR-T therapy and hematopoietic stem cell transplantation	
10:50 – 11:00	Discussion	José Antonio Flores (ES)
11:00 – 11:30	Coffee Break	
11:30 – 13:00	Session II: HSCT and Gene therapy in PIDS and metabolic disorders (IEWP) Chairs: Maria Ester Bernardo (IT) & Anna-Lisa Lanz (DE)	
11:30 – 11:45	Indications to allo-HSCT vs. HSC-GT in LSDs	Maria Ester Bernardo (IT)
11:45 – 12:10	Indications to allo-HSCT vs. HSC-GT in PIDs	Claire Booth (UK)
12:10 – 12:45	Which haploidentical platform to be employed in PID patients (TCR ab vs. pCY)?	Bénédicte Neven (FR)
12:45 – 13:00	Discussion	
13:00 – 14:00	Lunch Break	
14:00 – 15:15	Session III: From Fanconi Anemia + MDS. (SAAWP + MDS-EWOG) Chairs: Luca Vinci (DE) & Su Han Lum (UK)	
14:00 – 14:25	HSCT in Fanconi Anaemia	Su Han Lum (UK)
14:25 – 14:50	HSCT in MDS/JMML	Luca Vinci (DE)
14:50 – 15:00	Case Presentation: A severe cutaneous graft-versus-host disease reaction in the setting of herpes simplex virus-1 infection and tissue repair deficiency	
15:00 – 15:15	Discussion	To be announced
15:15 – 15:45	Coffee Break	
15:45 – 16:55	Session IV: HSCT vs Gene therapy in hemoglobinopathies (HWP) Chairs: Josu de la Fuente (UK) & Esraa Khalil (OM)	
15:45 – 16:10	HSCT and gene therapy in sickle cell disease	Josu de la Fuente (UK)
16:10 – 16:40	HSCT and gene therapy in thalassaemia	Mattia Algeri (IT)
16:40 – 16:50	Case Presentation First experience of allogeneic hematopoietic stem cell transplantation for sickle cell disease patients in a low resource country (Tanzania)	
16:50 – 17:00	Case Presentation Cerebral infarcts associated with micro embolic phenomena in the setting of infective endocarditis after allogeneic hematopoietic stem cell transplantation for sickle cell disease	Catherine Mhando (TZ)
17:00 – 17:45	Keynote Lecture (Main Room) Chair: Annalisa Ruggeri (IT) <i>Further information will be available soon.</i>	Lucas Anastacio (BR)
		Éliane Gluckman (FR)

09:00 – 10:00	Session IX: Complications after HCT Chairs: <i>Isabel Sanchez - Ortega (ES) & Ibrahim Yakoub-Agha (FR)</i>	
09:00 – 09:15	Early Endothelial Complications	Ibrahim Yakoub-Agha (FR)
09:15 – 09:25	Neurological complications	Giorgio Orofino (IT)
09:25 – 09:40	Improving infectious complications	José Luis Piñana (ES)
09:40 – 09:50	<i>Case Presentation:</i> Refractory post-transplant associated thrombotic microangiopathy in an adult patient with severe aplastic anaemia: exploring diagnostic and therapeutic challenges	Andrea Lattanzi (IT)
09:50 – 10:00	<i>Case Presentation:</i> Haemophagocytic Lymphohistiocytosis and EBV reactivation in severe Systemic Sclerosis after Autologous Transplant	Maria Chiara Auriemma (IT)
10:00 – 11:15	Session X: Optimizing Outcomes in Relapse Management Chairs: <i>To be announced & Jürgen Kuball (NL)</i>	
10:00 – 10:15	Immune Escape in Relapse	Cristina Toffalori (IT)
10:15 – 10:30	Role of DLI to improve outcomes	Jürgen Kuball (NL)
10:30 – 10:45	Graft manipulation for better outcomes	Peter Lang (DE)
10:45 – 10:55	<i>Case Presentation:</i> Management of Post-Transplant Relapse in a Young Adult Patient with Acute Myeloid Leukaemia: A Clinical Case	<i>To be announced</i>
10:55 – 11:05	<i>Case Presentation:</i> Durable Remission with Glofitamab Post- HSCT in a Patient with Relapsed/Refractory Burkitt Lymphoma with CNS Involvement	Yashashree Gupta (UK)
11:05 – 11:15	<i>Case Presentation:</i> CC-486 as a Bridge to Allogeneic Transplantation in TP53-Mutated MDS del(5q): A Case Report and Reflection on GvHD Management in the Elderly	Anna Francesio (IT)
11:15 – 11:45	Coffee Break	
11:45 – 12:45	Session XI: Next-Generation Strategies in HCT and CAR-T Chairs: <i>Nicolaus Kröger (DE) & Alberto Mussetti (ES)</i>	
11:45 – 12:00	Measurable residual disease	Nicolaus Kröger (DE)
12:00 – 12:15	Using Machine Learning and AI in HCT and CAR-T	Adrian Mosquera Orgueira (ES)
12:15 – 12:30	What's next in cellular therapy?	Moniek de Witte (NL)
12:30 – 12:40	<i>Case Presentation:</i> Donor-derived CD45RA ⁺ T-Cell infusion for disseminated Adenovirus infection following haploidentical HSCT in a pediatric patient with CAEBV and Hodgkin Lymphoma	Francesca Ciritella (IT)
12:40 – 12:45	Discussion and Q&A	
12:45 – 13:00	Poster awards and Closing Remarks Chairs: <i>Anna Sureda (ES)</i>	